DDInter1311 DDInter826
Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus. It is also found in plants and is used pharmacologically as a sympathomimetic.
Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonylurea drug group, glipizide displays rapid absorption and onset of action with the shortest half-life and duration of action, reducing the risk for long-lasting hypoglycemia that is often observed with blood glucose-lowering agents. Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip®.
Norepinephrine {u} (Compound) causes {v} (Side Effect) Arrhythmia
Arrhythmia {u} (Side Effect) is caused by {v} (Compound) Glipizide
Norepinephrine {u} (Compound) resembles {v} (Compound) Methyldopa
Methyldopa {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glipizide
Norepinephrine {u} (Compound) resembles {v} (Compound) Isoprenaline
Isoprenaline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Norepinephrine {u} (Compound) resembles {v} (Compound) Dopamine
Dopamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Norepinephrine {u} (Compound) causes {v} (Side Effect) Arrhythmia
Arrhythmia {u} (Side Effect) is caused by {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Glipizide
Norepinephrine {u} (Compound) causes {v} (Side Effect) Hyperhidrosis
Hyperhidrosis {u} (Side Effect) is caused by {v} (Compound) Glyburide
Glyburide {u} (Compound) resembles {v} (Compound) Glipizide
Norepinephrine {u} (Compound) resembles {v} (Compound) Methyldopa
Methyldopa {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glimepiride
Glimepiride {u} (Compound) resembles {v} (Compound) Glipizide
Norepinephrine {u} (Compound) resembles {v} (Compound) Isoprenaline
Isoprenaline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glimepiride
Glimepiride {u} (Compound) resembles {v} (Compound) Glipizide
Norepinephrine {u} (Compound) resembles {v} (Compound) Dopamine
Dopamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glimepiride
Glimepiride {u} (Compound) resembles {v} (Compound) Glipizide
Norepinephrine {u} (Compound) resembles {v} (Compound) Levonordefrin
Levonordefrin {u} (Compound) resembles {v} (Compound) Dopamine
Dopamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Norepinephrine (Compound) causes Arrhythmia (Side Effect) and Arrhythmia (Side Effect) is caused by Glipizide (Compound)
Norepinephrine (Compound) resembles Methyldopa (Compound) and Methyldopa may cause a minor interaction that can limit clinical effects when taken with Glipizide
Norepinephrine (Compound) resembles Isoprenaline (Compound) and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Norepinephrine (Compound) resembles Dopamine (Compound) and Dopamine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Norepinephrine (Compound) causes Arrhythmia (Side Effect) and Arrhythmia (Side Effect) is caused by Gliclazide (Compound) and Gliclazide (Compound) resembles Glipizide (Compound)
Norepinephrine (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Glyburide (Compound) and Glyburide (Compound) resembles Glipizide (Compound)
Norepinephrine (Compound) resembles Methyldopa (Compound) and Methyldopa may cause a minor interaction that can limit clinical effects when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Norepinephrine (Compound) resembles Isoprenaline (Compound) and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Norepinephrine (Compound) resembles Dopamine (Compound) and Dopamine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Norepinephrine (Compound) resembles Levonordefrin (Compound) and Levonordefrin (Compound) resembles Dopamine (Compound) and Dopamine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide